Xenon Pharmaceuticals Inc.XENEEarnings & Financial Report
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for neurological and rare disorders. Its core pipeline targets epilepsy, migraine and other central nervous system diseases, serving patients mainly across North America and Europe via partnerships to advance clinical candidates.
Revenue
$0
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
Xenon Pharmaceuticals Inc. Q4 FY2024 Financial Summary
Xenon Pharmaceuticals Inc. reported revenue of $0 for Q4 FY2024, with a net profit of N/A (down 46.8% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2024 |
Xenon Pharmaceuticals Inc. Annual Revenue by Year
Xenon Pharmaceuticals Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $7.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $7.5M |
| 2024 | $0 |
Xenon Pharmaceuticals Inc. Quarterly Revenue & Net Profit History
Xenon Pharmaceuticals Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | N/A | N/A |
| Q3 FY2025 | $0 | — | $-90.9M | N/A |
| Q2 FY2025 | $0 | — | $-84.7M | N/A |
| Q1 FY2025 | $7.5M | — | $-65.0M | -867.3% |
| Q4 FY2024 | $0 | — | N/A | N/A |
| Q3 FY2024 | $0 | — | $-62.8M | N/A |
| Q2 FY2024 | $0 | — | $-57.9M | N/A |
| Q1 FY2024 | $0 | — | $-47.9M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $7.5M | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $919.0M | $884.0M | $835.9M | $798.1M | $743.3M | $674.3M | $607.8M | $633.2M |
| Liabilities | $31.3M | $40.0M | $38.1M | $43.2M | $39.3M | $40.3M | $48.3M | $51.4M |
| Equity | $887.7M | $844.0M | $797.8M | $754.9M | $704.0M | $634.0M | $559.5M | $581.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-46.2M | $-31.2M | $-49.7M | $-181.4M | $-61.7M | $-64.2M | $-71.8M | $-279.1M |